Dergiler / Balkan Medical Journal / 2020 / Cilt: 37 - Sayı: 5

Clinicopathologic Features of Gastroenteropancreatic Neuroendocrine Tumors: A Single-center Experience

Sayfa
281–286
Yayın Tarihi
2022-10-11
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Moreover, grade (hazard ratio: 8.34, 95% confidence interval:2.16-32.22, p=0.01) and presence of metastasis at diagnosis (hazardratio: 3.18, 95% confidence interval: 1.30-7.77, p=0.01) independentlypredicted overall survival in multivariate model following adjustmentfor age and gender.Conclusion: Higher-grade and presence of metastasis at diagnosis arenegative independent prognostic indicators of survival in patients withgastroenteropancreatic neuroendocrine tumors.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background: Gastroenteropancreatic neuroendocrine tumors, aheterogeneous group of neoplasms, originates from the neuroendocrinesystem of the gastrointestinal tract and pancreas.
📊
Temel Bulgular & Veri:We investigated the clinical, pathological,survival features, and prognosis of patients with gastroenteropancreaticneuroendocrine tumors (n=128) admitted to the medical oncologydepartment between year 2003 and 2014.
💡
Sonuç & Katkı:Moreover, grade (hazard ratio: 8.34, 95% confidence interval:2.16-32.22, p=0.01) and presence of metastasis at diagnosis (hazardratio: 3.18, 95% confidence interval: 1.30-7.77, p=0.01) independentlypredicted overall survival in multivariate model following adjustmentfor age and gender.Conclusion: Higher-grade and presence of metastasis at diagnosis arenegative independent prognostic indicators of survival in patients withgastroenteropancreatic neuroendocrine tumors.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:2003 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Background: Gastroenteropancreatic neuroendocrine tumors, aheterogeneous group of neoplasms, originates from the neuroendocrinesystem of the gastrointestinal tract and pancreas. There are limitednumber of studies investigating neuroendocrine tumors in Turkey.Aims: To define the clinicopathologic, demographic, and survivalfeatures of patients with gastroenteropancreatic neuroendocrinetumors.Study Design: A retrospective observational cohort study.Methods: We reviewed hospital records of patients and data wasanalyzed retrospectively. We investigated the clinical, pathological,survival features, and prognosis of patients with gastroenteropancreaticneuroendocrine tumors (n=128) admitted to the medical oncologydepartment between year 2003 and 2014. Survival estimation wasperformed by the Kaplan-Meier method. Univariate and multivariateCox regression models were utilized to investigate the prognosticfactors for survival.Results: Of 128 patients with gastroenteropancreatic neuroendocrinetumors, 61 (47.7%) were female and 67 (52.3%) were male. Themost common site of the tumor was stomach (36.7%), while themost common stage of tumor at diagnosis was stage 4 (40.9%). Themedian follow-up period was 37 months, while the 3- and 5-yearoverall survival rates were 78% and 69%, respectively. The factorssignificantly affecting overall survival rate were clinical stage, grade,presence of metastasis at diagnosis, and Ki-67 proliferation index.These factors were associated with the 3- and 5-year overall survivalrate. Moreover, grade (hazard ratio: 8.34, 95% confidence interval:2.16-32.22, p=0.01) and presence of metastasis at diagnosis (hazardratio: 3.18, 95% confidence interval: 1.30-7.77, p=0.01) independentlypredicted overall survival in multivariate model following adjustmentfor age and gender.Conclusion: Higher-grade and presence of metastasis at diagnosis arenegative independent prognostic indicators of survival in patients withgastroenteropancreatic neuroendocrine tumors.

🔖

Bu Makaleye Atıf Yap

YALÇIN, Ş., ESİN, E., TELLİ, T. A. (2022). Clinicopathologic Features of Gastroenteropancreatic Neuroendocrine Tumors: A Single-center Experience. Balkan Medical Journal, Cilt: 37 - Sayı: 5, 281–286. https://ajindex.com/articles/460886

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Oberg K. Neuroendocrine gastrointestinal tumors-a condensed overview of diagnosis and treatment. Ann Oncol 1999;10(Suppl 2):3-8
  2. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Díaz-Pérez JA, Martínez Del Prado MP, Alonso Orduña V, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 2010;21:1794- 803
  3. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-72
  4. Auernhammer CJ, Göke B. Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. Gut 2011;60:1009-21
  5. Lepage C, Rachet B, Coleman MP. Survival from malignant digestive endocrine tumors in England and Wales: a population-based study. Gastroenterology 2007;132:899-904
  6. Pape UF, Berndt U, Müller-Nordhorn J, Böhmig M, Roll S, Koch M, et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2008;15:1083-97
  7. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010;39:707-12
  8. Rindi G, Arnold R, Bosman FT, Copella C, Klimstra DS, Klöppel G, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman TF, Carneiro F, Hruban RH, Theise ND, editors. WHO Classification of Tumours of the Digestive System, 4th ed. International Agency for Research on cancer (IARC), Lyon; 2010:13
  9. Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 2013;24:152-60
  10. Basturk O, Yang Z, Tang LH, Hruban RH, Adsay V, McCall CM, et al. The highgrade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol 2015;39:683-90
  11. Burnik FS, Yalcin S. NFKB1-94 insertion/deletion ATTG polymorphism in gastroenteropancreatic neuroendocrine tumors. Chemotherapy 2009;55:381-5
  12. Jiao Y, Shi C, Edil BH, de Wil